Table 2 Factors associated with Romosozumab nonadherence.
From: Risk factors and reasons for romosozumab nonadherence in a case-control study
Crude OR | 95% CI | p-value | Adjusted OR | 95% CI | p-value | |
|---|---|---|---|---|---|---|
Age at first treatment | ||||||
< 60 years | Ref. | Ref. | ||||
60–69 years | 1.733 | 0.443–6.789 | 0.430 | 1.833 | 0.435–7.717 | 0.409 |
70–79 years | 2.489 | 0.703–8.814 | 0.158 | 3.287 | 0.812–13.3 | 0.095 |
≥ 80 years | 1.533 | 0.437–5.38 | 0.504 | 2.511 | 0.612–10.298 | 0.201 |
Sex | ||||||
Female | Ref. | Ref. | ||||
Male | 14.161 | 1.794-111.778 | 0.012 | 9.03 | 1.093–74.581 | 0.041 |
Romosozumab expenses | ||||||
Full subsidy | Ref. | Ref. | ||||
Self-payment | 2.777 | 1.297–5.945 | 0.009 | 2.756 | 1.14–6.663 | 0.024 |
Fracture history | ||||||
None | Ref. | Ref. | ||||
Within 1 year before treatment | 0.557 | 0.242–1.286 | 0.170 | 0.614 | 0.213–1.773 | 0.368 |
History of orthopedic surgery | ||||||
None | Ref. | Ref. | ||||
Within 1 year before treatment | 0.949 | 0.462–1.953 | 0.888 | 1.312 | 0.51–3.375 | 0.574 |
During treatment | 1.600 | 0.428–5.982 | 0.485 | 1.302 | 0.284–5.965 | 0.734 |
